key: cord-0794742-dm8yl4xu authors: Long, Quan-xin; Deng, Hai-jun; Chen, Juan; Hu, Jieli; Liu, Bei-zhong; Liao, Pu; Lin, Yong; Yu, Li-hua; Mo, Zhan; Xu, Yin-yin; Gong, Fang; Wu, Gui-cheng; Zhang, Xian-xiang; Chen, Yao-kai; Li, Zhi-jie; Wang, Kun; Zhang, Xiao-li; Tian, Wen-guang; Niu, Chang-chun; Yang, Qing-jun; Xiang, Jiang-lin; Du, Hong-xin; Liu, Hua-wen; Lang, Chunhui; Luo, Xiao-he; Wu, Shao-bo; Cui, Xiao-ping; Zhou, Zheng; Wang, Jing; Xue, Cheng-jun; Li, Xiao-feng; Wang, Li; Tang, Xiao-jun; Zhang, Yong; Qiu, Jing-fu; Liu, Xia-mao; Li, Jin-jing; Zhang, De-chun; Zhang, Fan; Cai, Xue-fei; Wang, Deqiang; Hu, Yuan; Ren, Ji-hua; Tang, Ni; Liu, Ping; Li, Qin; Huang, Ai-long title: Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice date: 2020-03-20 journal: nan DOI: 10.1101/2020.03.18.20038018 sha: 30c8067785e821458e0648954a2b5a7ca1ae7023 doc_id: 794742 cord_uid: dm8yl4xu Background We aim to investigate the profile of acute antibody response in COVID-19 patients, and provide proposals for the usage of antibody test in clinical practice. Methods A multi-center cross-section study (285 patients) and a single-center follow-up study (63 patients) were performed to investigate the feature of acute antibody response to SARS-CoV-2. A cohort of 52 COVID-19 suspects and 64 close contacts were enrolled to evaluate the potentiality of the antibody test. Results The positive rate for IgG reached 100% around 20 days after symptoms onset. The median day of serocon-version for both lgG and IgM was 13 days after symptoms onset. Seroconversion of IgM occurred at the same time, or earlier, or later than that of IgG. IgG levels in 100% patients (19/19) entered a platform within 6 days after seroconversion. The criteria of IgG seroconversion and ≥ 4-fold increase in the IgG titers in sequential samples together diagnosed 82.9% (34/41) of the patients. Antibody test aided to confirm 4 patients with COVID-19 from 52 suspects who failed to be confirmed by RT-PCR and 7 patients from 148 close contacts with negative RT-PCR. Conclusion IgM and IgG should be detected simultaneously at the early phase of infection. The serological diagnosis criterion of seroconversion or ≥ 4-fold increase in the IgG titer is suitable for a majority of COVID-19 patients. Serologic test is helpful for the diagnosis of SARS-CoV-2 infection in suspects and close contacts. The rapid spread of Coronavirus Disease 2019 (COVID-19) worldwide has raised concern around the world. The outbreak of COVID-19 first started in Wuhan of Human immune responses to a novel pathogen with both innate and adaptive arms. One aspect of the adaptive immunity is humoral response that features the production of antibodies recognizing specific determinants of antigens called epitopes. Some of the antibodies produced can protect the host from future infection by the same pathogens. Studies on severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) showed that antibodies were detectable in 80%-100% patients at 2 weeks after illness onset [1, 2, 3, 4] , and the antibodies can persist for at least 12 years [5] . Moreover, the profile of antibody responses might be . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 20, 2020. . https://doi.org/10.1101/2020.03.18.20038018 doi: medRxiv preprint correlated to the severity of disease and outcome in MERS [6, 7] . Currently, as antibody detection for COVID-19 has not been broadly developed, the antibody response against SARS-CoV-2 remains nearly unknown. In this study, we depicted the profiles of acute antibody response against SARS-CoV-2 through a cross-section analysis of 285 patients and a follow-up study of 63 patients. We also demonstrated the clinical application of antibody test in facilitating the diagnosis of COVID-19 both in suspects and asymptomatic close contacts. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 20, 2020. A total of 285 COVID-19 patients for the cross-section study were enrolled from 3 designated hospitals of Chongqing, a province-level municipality adjacent to Hubei province,which is the start-point and at the center of COVID-19 outbreak in China. These three hospitals, Chongqing Three Gorges Central Hospital (TGH), Yongchuan Hospital Affiliated to Chongqing Medical University (CQMU) (YCH), and The Public Health Center of Chongqing (PHCC), were assigned by the Chongqing municipal people's government to admit patients from 3 designated areas indicated in Continuous variables were expressed as median (interquartile range, IQR) and compared with the Mann-Whitney U test; categorical variables were expressed as number (%) and compared by χ ² test or Fisher's exact test. P value less than 0.05 was considered statistically significant. Statistical analyses were performed using the R software, version 3.6.0. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 20, 2020. . https://doi.org/10.1101/2020.03.18.20038018 doi: medRxiv preprint 285 cases of COVID-19 patients admitted to 3 designated hospitals were enrolled in this cross-section study. The median age of these enrolled patients was 47 years (IQR, 34-56 years) and 55.4% were males. 103 patients had an history of exposure to transmission sources, while 262 patients with clear records of symptoms onset. 39 of 285 cases were classified as severe or critical illness condition according to the guidelines (Table S1 ). For laboratory parameters of the patients, white blood cell, neutrophil D-dimer, hypersensitive troponin I, procalcitonin, CRP (C-reactive protein), lactate dehydrogenase, alanine aminotransferase and aspartate aminotransferase were higher in severe/critical patients, while mild patients had higher level of lymphocyte counts, which is consistent with recent reports [8, 9] (table S2) . Antibody detection rate based on the number of days after onset of symptoms were determined and summarized in Figure There were 20 severe patients who were at the 2 nd week after symptoms onset when sampling, and 13 severe patients were at the 3 rd week when sampling. As shown in Fig. 1C , IgG and IgM titers in severe group were higher than those in the non-severe . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 20, 2020. . https://doi.org/10.1101/2020.03.18.20038018 doi: medRxiv preprint group, although significant statistic difference is only observed in IgG level of 2 weeks group (P=0.001). To investigate the longitudinal profiles in the IgG and IgM, 63 confirmed COVID-19 patients in the cross-section study were followed up further. A total of 281 sequential serum samples were collected and tested in parallel for the IgG and IgM against SARS-CoV-2. Of the 63 patients, the overall seroconversion rate was 96.8% (61/63) over the follow-up period. Two patients, a 11-year old girl and her mother, maintained IgG and IgM-negative status during hospitalization, indicating that they did not undergo serological conversion during the observation period. Unfortunately, these two patients were lost for follow-up and the delayed seroconversion cannot be excluded. Serological courses could be followed for 27 patients who were initially seronegative and then underwent a seroconversion during the observation (IgG seroconversion in 19 patients, IgM seroconversion in 20 patients and both seroconversion in 13 patients). All these patients achieved a seroconversion of IgG or IgM within 20 days after symptoms onset. The median day of seroconversion for both lgG and IgM was 13 days (after symptoms onset) (Fig. 3A) . Three types of seroconversion can be observed: synchronous seroconversion of IgG and IgM (10 cases); IgM seroconverted earlier than that of IgG (7 cases); IgM seroconverted later than that of IgG (10 cases). The longitudinal changes of antibody in 6 representative patients of three types were shown in Fig. 3B-D and Fig. S2 . Based on this finding, we recommend that either IgM or IgG seroconversion be used as a confirmation criterion of recent SARS-CoV-2 infection. We tried to identify the factors associated with the different seroconversion types, but found no association between these types and age or gender or hospitalization time (data not shown). To analyzed the dynamics changes of the IgG levels in acute response, we normalized the time of the last negative test points of 19 patients who underwent IgG seroconversion during hospitalization. As shown in Fig. 3A , the IgG levels in all the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. .9%) did not achieve a seroconversion before discharge (achieved consecutive RT-PCR -). These data indicate that the criterion of "≥ 4-fold increase in IgG titer" might be too stringent to confirm a minority of COVID-19 patients. To evaluate the potentiality of the serological test in COVID-19 diagnosis, 52 COVID-19 suspects admitted to Wanzhou People's Hospital (Chongqing, China) who had respiratory symptoms or abnormal pulmonary imaging, but with negative RT-PCR in at least 2 sequential tests were enrolled. Four of the 52 patients showed . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 20, 2020. . https://doi.org/10.1101/2020.03.18.20038018 doi: medRxiv preprint positive IgG (3/4) or IgM (3/4) in their first samples (Fig. 4) . Patients 3 showed an over 4-fold increase in IgG at the latter time point. Interestingly, RT-PCR test of patient 3's sample became positive one day between the two sampling, confirming the infection of SARS-CoV-2. An increase in the titer of IgM was observed in the 3 sequential samples from patient 1 (< 2-folds). Patient 2 was positive in both the IgG and IgM. Patient 4 had high IgG and IgM titers, more than 100-fold and 10-fold higher respectively, than the cut-off values at both time points. Although the latter 3 patients did not show a seroconversion or a > 4-fold change of IgG titers between sequential samples, we still support a COVID-19 diagnosis for them. We next used the serological test in a cluster of 164 close contacts identified by Chongqing CDC. A couple travelled back from Wuhan city, who were confirmed to be SARS-CoV-2 infection on Feb 4, 2020, were deemed as the 1 st generation patients of this network. All other cases in this cohort were closely contacted (either directly or indirectly) with this couple during Jan 20 to Feb 6, 2020. A total of 16 out of 164 cases were confirmed by RT-PCR during Jan 31 to Feb 9, 2020, with 3 cases reporting no symptoms. The other 148 cases were no symptoms and negative in RT-PCR tests. On March 1, 2020, serum samples were collected from these 164 cases for antibody tests. The 16 RT-PCR confirmed cases were positive in IgG or/and IgM. Strikingly, 7 of the 148 cases who were excluded previously by negative nucleic acid results also showed positive results in IgG or/and IgM, indicating that 4.3% (7/162) of close contacts were missed by nucleic acid test. In addition, about 6.1% (10/164) of this cohort were asymptomatic infection. The features of the antibody responses against SARS-CoV-2 give us hints for the application of the serological test in the diagnosis of COVID-19. Firstly, almost all . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 20, 2020. (Fig. 3B, middle panel) . This finding highlights the importance of collecting the first sample as early as possible. On the other hand, we argue that for those patients missed the ideal sampling window, a second serological test several days (for example, 3 days) later that confirms the first positive results would be sufficient to confirm the diagnosis, if with symptoms or chest imaging evidence simultaneously. The asymptomatic infection poses a special challenge in the prevention of COVID-19, since symptoms are usually used as important indicator for COVID-19. Asymptomatic individual with infection will become a transmission source if not be contained and quarantined. We surveyed a cohort of 164 close contacts and identified 4.3% (7/164) patients with occult infection which were missed by symptoms screening and nucleic acid test. Adding those identified by RT-PCR, the percentage of asymptomatic infection was as high as 6.1% in this cohort. Thus, it is necessary to . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 20, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. acute (ideally during the first week of illness) and convalescent serum samples was recommended by the WHO as confirmation criteria. We tested whether these criteria are suitable for COVID-19. Among the 41 patients, 29 can be diagnosed by these . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 20, 2020. . https://doi.org/10.1101/2020.03.18.20038018 doi: medRxiv preprint criteria and 5 cannot. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Serological assays for emerging coronaviruses: challenges and pitfalls Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection Profile of specific antibodies to the SARS-associated coronavirus Kinetics of Serologic Responses to MERS Coronavirus Infection in Humans, South Korea. Emerg Infect Dis Long-Term Persistence of IgG Antibodies 1 in SARS-CoV Infected Healthcare Workers. medRxiv Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity Clinical features of patients infected with 2019 novel coronavirus in Wuhan Clinical Characteristics of Coronavirus Disease The copyright holder for this preprint this version posted March 20, 2020. . https://doi.org/10.1101/2020.03.18.20038018 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted March 20, 2020. . https://doi.org/10.1101/2020.03.18.20038018 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 20, 2020. . https://doi.org/10.1101/2020.03.18.20038018 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 20, 2020. . https://doi.org/10.1101/2020.03.18.20038018 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 20, 2020. . https://doi.org/10.1101/2020.03.18.20038018 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 20, 2020. . https://doi.org/10.1101/2020.03.18.20038018 doi: medRxiv preprint